From Cost Optimization to Supply Resilience: The Impact of the Critical Medicines Act

For decades, pharmaceutical supply chains have balanced patient safety, regulatory compliance, supply continuity, and operational efficiency. Increasing globalization and manufacturing specialization have also created growing dependencies on a limited number of suppliers, manufacturing sites, and regions for certain critical medicines and pharmaceutical ingredients.

Those dependencies are now under greater scrutiny. Europe’s medicine shortages have increasingly been described as structural rather than temporary, and the European Commission proposed the Critical Medicines Act in March 2025 as part of a broader effort to strengthen availability and security of supply for essential medicines across the EU.

As of 2026, the legislative process has advanced significantly. The European Parliament adopted proposals in January 2026 to improve the availability and supply of essential medicines, and EU institutions reached a provisional agreement in May 2026. European Parliament and EMA

Where the Critical Medicines Act Fits

The Critical Medicines Act is not a standalone initiative. It complements the European Union’s broader pharmaceutical reform agenda and ongoing efforts to address medicine shortages, including the development of a Union list of critical medicines and enhanced coordination mechanisms across Member States.

Its role is more specific: addressing supply chain vulnerabilities and manufacturing capacity gaps that existing frameworks have struggled to resolve. The European Commission describes the Act as a way to strengthen availability, supply, and production of critical medicines in the EU, with measures around strategic projects, procurement, investment, and international partnerships. European Commission Critical Medicines Act

The policy direction is clear. Ensuring access to critical medicines requires more than responding to shortages after they occur. It requires building resilience into the pharmaceutical supply chain itself.

What Problem Is the CMA Trying to Solve?

A recurring theme across EU policy discussions is dependency on concentrated supply sources for certain medicines and pharmaceutical ingredients. Pharmaceutical supply chains have become highly specialized, often relying on a limited number of suppliers, manufacturing sites, or regions for critical medicines, active pharmaceutical ingredients, and key starting materials.

These networks have supported global access and operational efficiency, but they also increase exposure to disruptions. COVID-19, geopolitical tensions, transportation disruptions, and recurring medicine shortages have shown how challenges affecting one supplier, site, or region can quickly ripple across multiple healthcare systems.

The CMA is intended to address these structural vulnerabilities by encouraging diversification of supply sources, strengthening manufacturing capacity, improving coordination across Member States, and supporting investment in strategically important pharmaceutical manufacturing capabilities.

Three Signals Supply Chain Leaders Should Pay Attention To

One of the most notable elements of the proposal is the concept of Strategic Projects. According to the European Commission, these projects are intended to strengthen the production, scaling, modernization, and resilience of critical medicine supply chains within the European Union, while benefiting from easier access to funding and faster procedures. European Commission

What This Means for Pharmaceutical Supply Chains

Even before final implementation details are settled, the CMA points toward a broader change in how pharmaceutical supply chains may be evaluated and managed. Alongside cost and efficiency, organizations may need to place greater emphasis on understanding and mitigating supply chain vulnerabilities.

• Single-source supplier dependencies
• Geographic concentration risks
• Time required to recover from disruption
• Flexibility within manufacturing and regulatory networks
• Visibility across suppliers, inventory, manufacturing, quality, and logistics

Practical Actions Organizations Can Take Today

Segment critical products

Not all products carry the same supply risk. Organizations should identify products that would likely be considered critical based on patient impact, supply availability, market importance, and substitution difficulty. Differentiated planning, sourcing, and service strategies can then be applied where they matter most.

Map upstream dependencies

Many supply risks originate several tiers upstream. Building visibility into APIs, key starting materials, critical suppliers, and geographic concentrations helps identify vulnerabilities before they become shortages.

Define resilience metrics

Resilience is hard to improve if it cannot be measured. Organizations should consider metrics such as dual-source coverage, Time-to-Recover, service levels for critical products, and supplier-concentration indicators.

Strengthen visibility and exception management

Supply chain resilience depends on timely, accurate information. Multi-tier supplier visibility, inventory transparency beyond internal facilities, and structured exception management all contribute to a stronger ability to detect and respond to disruptions before they impact supply.

A disruption rarely begins as a shortage. More often, it starts as a delayed raw-material delivery, a quality deviation, a manufacturing delay, a testing backlog, or an unexpected shift in supplier performance. Without connected visibility across these processes, organizations often discover issues only after they have affected production schedules or customer supply commitments.

Building Resilience Requires More Than Inventory

Conversations about supply chain resilience often gravitate toward inventory buffers. Inventory can help absorb disruption, but it does little to address the underlying vulnerabilities that create disruption in the first place.

Building resilience requires a broader set of capabilities, including supplier diversification, network flexibility, scenario planning, end-to-end visibility, and rapid exception response. Organizations should be able to answer core questions such as:

• Which critical products are currently exposed to supply risk?
• Where are the primary dependencies within the supply network?
• Which supplier, manufacturing, quality, or logistics exceptions could affect supply over the next 30, 60, or 90 days?
• How quickly can potential disruptions be identified, escalated, and resolved?
• What inventory, work-in-process, or alternative supply options are available to mitigate risk?

The ability to answer these questions consistently requires more than extra stock. It requires visibility into where risks exist, how those risks could affect supply, and what actions can be taken before patient access is affected.

Looking Ahead

The Critical Medicines Act continues to move through the legislative process, and several implementation details still depend on final adoption and national execution. However, the overall direction is increasingly clear. European policymakers are not simply responding to individual medicine shortages. They are addressing the structural vulnerabilities that leave critical medicines exposed to supply disruption.

For organizations operating within or supplying to the European market, the question is becoming less about whether resilience will matter and more about how quickly capabilities can be developed to support it.

Many of the actions discussed here represent no-regret investments. Mapping critical dependencies, strengthening visibility, improving exception management, diversifying supply sources, and building resilience metrics can deliver operational benefits today regardless of the final form of the legislation.

Supply chain transformations require time. Waiting for the final regulatory text may reduce uncertainty, but it also shortens the window available to prepare. Organizations that begin strengthening resilience today will be better positioned to adapt to evolving policy expectations and navigate future disruptions in an increasingly complex pharmaceutical landscape.